Therakind completes Management Buy-Out
Positions Company for innovation focused growth
London, England – March 2024 – Therakind Limited (“Therakind”), a specialty pharmaceutical company focused on developing and delivering niche medicines for difficult-to-treat patient groups, today announces that it has completed a Management Buy-Out (“MBO”). The company will be led by the experienced senior management team which has been working together in the pharmaceutical industry for over 20 years.
Dr Susan Conroy, CEO of Therakind, said: “We are delighted to take Therakind into the hands of management. The team deeply believes in Therakind’s purpose and aims, which are focused on improving patient care through innovation and delivery of proprietary and partnered drug candidates, particularly in difficult-to-treat patient groups, an often underserved market. The MBO will allow us to prioritise our business growth through a lens of innovation and we believe this focus will bring an incredibly bright future for the Company.”
Therakind, a London-based pharmaceutical company, has successfully brought three pharmaceutical products to market, collectively obtaining FDA, EMA, and MHRA approval. The Therakind team, experienced in all aspects of pharmaceutical development, remains committed to addressing unmet medical needs in drug development.
Currently, Therakind is focused on the development of DriDose®, its dry powder nasal drug delivery device range. The Company is actively seeking new opportunities and partnerships to bring novel nasal products to the market. Leveraging its expertise in formulation development, Therakind collaborates closely with pharmaceutical companies to produce dry powder nasal formulations of partner candidates alongside development of its proprietary pipeline.
DriDose® includes both single-use and reusable versions, each capable of being modified to accommodate different powder-loading capacities. The reusable device is designed to reduce plastic waste associated with single-use devices and injections.The DriDose® device aims to simplify drug delivery and provide an alternative to nasal sprays, nebulizers, tablets, and injections. DriDose® technology has been validated in a clinical trial and tested with a range of molecules in bothin vivoandin vitrosettings. For companies interested in partnering DriDose® with Therakind, please contact us atbd@therakind.com
For more information, please contact:
Therakind Ltd
Dr Susan Conroy, Chief Executive Officer
Tel: ++44 (0) 208 346 603
Email: info@therakind.com
Website: www.therakind.com
About Therakind Limited
Therakind is a specialty pharmaceutical company with a proprietary and partnered pipeline focused on improving medicine adherence through more patient-friendly dosing options. We have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to incorporate the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups. To date, we have developed and obtained marketing authorisations for three products and our intranasal device for the delivery of a dry powder drug formulation, DriDose®, is available for co-development.
To find out more, please visit www.therakind.com